New ALS Drug Begins Global Testing to Restore Nerve Function

Scientists have launched the first human trials of TRCN-1023, an experimental drug designed to help restore communication between nerves and muscles in people with ALS. The treatment targets a protein malfunction that affects the vast majority of patients with the devastating disease.

Trace Neuroscience is now testing the drug in two global trials spanning six countries, including the U.S., U.K., Canada, Germany, Netherlands, and China. The first patients in China have already received doses, marking a significant milestone for a disease that has limited treatment options.

ALS destroys the nerve cells responsible for muscle movement, gradually stealing away a person's ability to walk, speak, swallow, and breathe. Current treatments can only slow the progression slightly, making new therapeutic options desperately needed.

TRCN-1023 works by correcting a critical error in how cells process genetic instructions. In most people with ALS, a protein called TDP-43 forms abnormal clumps that disrupt the normal production of UNC13A, a protein essential for nerves to communicate with muscles.

The new drug acts like a molecular editor, binding to genetic material and guiding cells to produce functional UNC13A protein. By restoring this protein, researchers hope to improve the signaling between nerves and muscles that keeps the body moving.

Dame Pamela Shaw, a neurology professor at the University of Sheffield leading one trial, called UNC13A "among the most promising targets in ALS research today." The approach has strong backing from both genetic studies and biological research.

The trials will enroll about 55 patients total who developed symptoms within the past two years. Participants will receive the drug through injections into the spinal canal and be monitored for 24 weeks, with an option to continue in a long-term extension.

Why This Inspires

What makes this trial particularly meaningful is how researchers designed it with input from ALS patients and their caregivers. Participants will wear digital sensors at home to track daily movement and complete speech assessments in their own environment, making the process less burdensome during an already difficult time.

The speed and global coordination of these trials reflects the urgency researchers feel. By testing the drug simultaneously across multiple countries, they can gather robust safety and effectiveness data faster than traditional sequential approaches.

This matters because ALS patients don't have time to wait. The disease progresses quickly, and every month counts when families are watching their loved ones lose abilities.

The therapy represents a fundamentally new approach, targeting the underlying protein dysfunction rather than just managing symptoms. If successful, it could benefit the vast majority of ALS patients, not just those with specific genetic mutations.

Global collaboration is accelerating hope for thousands of families facing this diagnosis.